Thus, developing an understanding of the importance of the NRF2–ARE pathway in cancer is an urgent need, and the development of NRF2 inhibitors would provide an opportunity for targeting chemoresistance or development chemotherapy (Figure 3). Here, NFE2L2 is linked to cancer.